Summary & Overview
CPT 81296: Targeted Familial MSH2 Mutation Testing
CPT code 81296 represents a targeted molecular diagnostic assay that detects known familial mutations in the MSH2 gene, a mismatch repair gene associated with hereditary nonpolyposis colorectal cancer (Lynch syndrome). This code matters nationally as targeted family-member testing supports cascade screening, cancer risk assessment, and personalized surveillance strategies for at-risk relatives.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find clinical context on what the assay covers, typical sites of service, and why this testing is distinct from broader sequencing panels. The publication summarizes payer coverage considerations, common billing modifiers, and areas where policies differ across major payers. It also outlines practical billing implications for laboratories and clinicians submitting claims for familial MSH2 variant testing.
Readers will gain benchmarks for utilization and coverage trends, explanations of coding scope, and a concise overview of policy and clinical implications for hereditary colorectal cancer risk evaluation. Data not available in the input is noted where specific payer policy details or utilization metrics would normally appear.
Billing Code Overview
CPT code 81296 describes a targeted genetic test performed by a laboratory analyst to detect known familial mutations in the mutS homolog 2 (MSH2) gene, also called the colon cancer or nonpolyposis type 1 gene. The service is a targeted molecular diagnostic test focused on identifying a specific mutation previously documented in the patient’s family.
Service type: Targeted genetic testing (molecular diagnostic testing for familial MSH2 mutations)
Typical site of service: Clinical molecular diagnostics laboratory
Clinical & Coding Specifications
Clinical Context
A 38-year-old patient with a strong family history of Lynch syndrome (hereditary nonpolyposis colorectal cancer) is referred for targeted molecular testing. A first-degree relative was previously documented to carry a pathogenic variant in the MSH2 gene. The patient receives pre-test genetic counseling, signs informed consent, and provides a blood sample (or buccal swab) for laboratory analysis. The molecular laboratory performs a targeted mutation analysis to detect the specific family-known MSH2 variant using PCR-based, Sanger sequencing, or allele-specific methods. Results are reported to the ordering clinician and genetic counselor, who integrate findings into surveillance and management planning for colorectal and extracolonic cancer risk.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When reporting the physician or pathologist interpretation separate from the laboratory technical work, if applicable. |
TC | Technical component | When billing only the laboratory technical portion and the reporting clinician is not billing the professional component. |